The invention provides methods and compositions for reducing or preventingfibrosis in a subject suffering from a fibrotic disorder by administering atherapeutically effective amount of at least one antagonist to the cytokinethymic stromal lymphopoietin to the subject. In one embodiment, the methodsand compositions further comprise administering at least one additionalantagonist to an additional profibrotic cytokine, growth factor or chemokine.